A Phase 3 interventional study of Parcopa in Parkinson's Disease, sponsored by UCB Pharma. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-09-04.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Parkinson Disease by UCB S.A. — none open to participants now, none under way, none of them phase 3. Parkinson Disease · UCB S.A..
Among the 44 studies in Parkinson Disease by UCB S.A., this one is one of 2 that started in 2005, is one of 19 in phase 3, and was the 1st registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 44 studies in Parkinson Disease by UCB S.A. is open now. The open studies under Parkinson Disease, anywhere →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 123 across the 34 interventional studies, 172 across the 6 observational. Of the 44 that completed or were terminated, 29 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Parkinson Disease by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a single dose of Parcopa or Sinemet are being compared in 10 subjects with Parkinson's disease. Subjects 40 years or older having idiopathic PD with Hoehn and Yahr state II or III are eligible if taking a stable dose of \< 200 mg carbidopa and \< 2000 mg levodopa daily. At both treatment visits, either Parcopa or Sinemet, plus a placebo of the opposite tablet (ODT or conventional) are administered. The dose is the same as the subject's prestudy regimen. The primary efficacy variable, time to onset of action, is the first postdose time when a 30% decrease (30% improvement) in the total score is achieved. All UPDRS evaluations are done by a rater blinded to the active treatment received by the subject.
See approved Package Insert for Adverse Event information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The record gives a start of Jun 2005, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.